他汀治疗与肾移植后动脉粥样硬化心血管事件发生率
本研究回顾性纳入2006至2019年单中心318例肾移植受者,评估他汀暴露与动脉粥样硬化心血管事件的关系及对血脂的生化疗效。
要点
- 按他汀治疗强度分层后结果一致。
核心结论
- 尽管血脂谱改善,他汀暴露与肾移植受者心血管事件减少无关。
- 需要更大规模的对照研究来确认或反驳这些结果。
研究设计与样本
- 单中心回顾性研究,连续纳入2006至2019年318例肾移植受者。
- 移植后使用他汀者为新发使用者,所有使用者他汀均用于心血管一级预防。
- 采用含他汀暴露为时间依赖协变量的Cox模型,拟合时变逆概率治疗加权(IPTW)评估他汀对动脉粥样硬化心血管事件及所有心血管事件的效果。
- 构建线性混合模型评估他汀的生化疗效。
主要发现
- 中位随访6.0(3.9-10.0)年期间,26例患者发生27次动脉粥样硬化心血管事件。
- 按他汀治疗强度分层后结果一致。
临床怎么用
- 该真实世界单中心回顾性长期随访研究显示,他汀暴露虽改善血脂谱,但未与心血管事件减少相关。
局限性
- 原文自述为真实世界、单中心、回顾性、长期随访研究。
- 原文指出需要更大规模的对照研究来确认或反驳这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Statins are recommended in kidney transplant recipients (KTRs)-a population with a high risk of major cardiovascular (CV) events. However, the literature data on the effectiveness of statins in KTRs are sparse and inconclusive. The present study's objective was to evaluate the association between statin exposure and atherosclerotic CV events in KTRs and the biochemical effectiveness of statins on the lipid profile. METHODS: A total of 318 consecutive KTRs managed at a single center between 2006 and 2019 were retrospectively included. Those exposed to statins after transplantation were incident users. In all users, statins were indicated for primary CV prevention. Lipid profiles, the occurrence of any atherosclerotic CV events (stroke, myocardial infarction, other atherosclerotic CV events and atherosclerotic CV deaths) were documented comprehensively. We applied Cox models that included statin exposure as a time-dependent covariate fitted with time-varying inverse probability treatment weighting (IPTW) to assess the effectiveness of statins on atherosclerotic CV events and on all CV events. We built linear mixed models to assess the biochemical effectiveness of statins. RESULTS: During a median (interquartile range) follow-up period of 6.0 (3.9-10.0) years, 27 atherosclerotic CV events occurred in 26 patients. In the Cox models fitted with time-varying IPTW, exposure to statins was not associated with a decrease in atherosclerotic CV events; the hazard ratio was 1.16 (95% confidence interval 0.53-2.53) (P = .700). In the linear mixed models, statin exposure was associated with significant decrease over time in triglyceride and low-density lipoprotein cholesterol concentrations (P < .001). These results were consistent when stratified for the intensity of statin therapy. CONCLUSION: Even though the lipid profile improved, statin exposure was not associated with a decrease in CV events in this real-life, single-center, retrospective, long-term follow-up study of a KTR cohort. Larger, controlled studies are needed to confirm or refute these results.
引用
- Nazoiri C, Liabeuf S, Brazier F, et al. Statin therapy and the incidence of atherosclerotic cardiovascular events after kidney transplantation. Nephrol Dial Transplant. 2024. PMID: 37791395. doi:10.1093/ndt/gfad217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。